TWST
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/E is N/A; Forward P/E is negative (-33.21), rendering traditional value metrics inapplicable.
- P/S ratio of 9.80 is excessive for a non-profitable firm
- P/B ratio of 8.41 indicates high premium
- Current price exceeds analyst target price
Revenue growth is positive at 16.9%, but EPS growth remains negative or negligible.
- Steady revenue growth
- Disruptive synthetic DNA technology potential
- No clear path to profitability
- Intense industry competition
Short-term momentum is strong, but long-term performance is poor.
- Recent 1-year price return of +81.2%
- 5-year change is -53.5%
- Consistent history of net losses
While not at immediate risk of bankruptcy due to cash/low debt, operational health is failing.
- Low Debt/Equity
- Strong Current Ratio
- Piotroski F-Score of 1/9 is a major red flag
- Negative ROE and ROA
Dividend Yield: N/A
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TWST and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TWST
Twist Bioscience Corporation
Primary
|
-53.5% | +355.4% | +81.2% | +87.5% | +40.7% | +9.1% |
|
ALHC
Alignment Healthcare, Inc.
Peer
|
+11.0% | +93.4% | +42.7% | +17.5% | -12.9% | -6.7% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
|
TMDX
TransMedics Group, Inc.
Peer
|
+298.9% | +27.5% | +29.0% | -5.7% | -0.7% | -0.2% |
|
IRTC
iRhythm Holdings, Inc.
Peer
|
+43.4% | -13.2% | +16.6% | -34.6% | -3.7% | -1.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TWST
Twist Bioscience Corporation
|
BEARISH | $3.84B | - | -16.8% | -19.6% | $62.61 | |
|
ALHC
Alignment Healthcare, Inc.
|
BEARISH | $3.85B | - | -0.7% | -0.0% | $19.22 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | Compare |
|
TMDX
TransMedics Group, Inc.
|
BULLISH | $3.91B | 23.28 | 54.2% | 31.4% | $113.13 | Compare |
|
IRTC
iRhythm Holdings, Inc.
|
NEUTRAL | $3.72B | - | -36.6% | -6.0% | $115.24 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-14 | LAPONIS ADAM | Chief Financial Officer | Sale | 3,000 | $165,000 |
| 2026-04-09 | LAPONIS ADAM | Chief Financial Officer | Sale | 2,597 | $129,562 |
| 2026-04-01 | STAROVASNIK MELISSA A | Director | Sale | 1,000 | $51,000 |
| 2026-03-20 | LEPROUST EMILY M | Chief Executive Officer | Sale | 1,742 | $76,276 |
| 2026-03-20 | GREEN PAULA | Officer | Sale | 297 | $13,005 |
| 2026-03-20 | CHO DENNIS | Officer | Sale | 354 | $15,500 |
| 2026-03-17 | CHESS ROBERT BRUCE | Director | Sale | 10,000 | $470,000 |
| 2026-03-17 | CHESS ROBERT BRUCE | Director | Option Exercise | 10,000 | $118,900 |
| 2026-03-06 | LEPROUST EMILY M | Chief Executive Officer | Sale | 2,423 | $112,490 |
| 2026-03-06 | GREEN PAULA | Officer | Sale | 935 | $43,408 |
| 2026-03-06 | WERNER ROBERT F. | Officer | Sale | 246 | $11,421 |
| 2026-03-06 | CHO DENNIS | Officer | Sale | 425 | $19,731 |
| 2026-02-23 | FINN PATRICK JOHN | President | Sale | 4,294 | $200,572 |
| 2026-02-23 | LEPROUST EMILY M | Chief Executive Officer | Sale | 7,205 | $336,544 |
| 2026-02-23 | GREEN PAULA | Officer | Sale | 1,465 | $68,430 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
TWST has incurred net losses in every period to date and expects to continue incurring significant losses, with no certainty of achieving profitability. The company faces substantial risks related to its dependence on disruptive synthetic DNA technology, intense industry competition, and a reliance on a limited number of large customers.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning TWST from our newsroom.